ALMS - NASDAQ
Alumis Inc. Common Stock
$20.57
+2.4%Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotalms
Total Non-Current Assets
Last Annual Value
93.71M
3-Year CAGR
156%
5-Year CAGR
76%
10-Year CAGR
33%
Alumis Inc. Common Stock Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Alumis Inc. Common Stock NASDAQ:ALMS | 93.71M | 37.2% | N/A | N/A | |
 Eton Pharmaceuticals, Inc. NASDAQ:ETON | 31.53M | 86.0% | 52.2% | N/A | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 510.00K | -69.5% | -48.2% | N/A | |
 Fulcrum Therapeutics, Inc. NASDAQ:FULC | 8.80M | -17.2% | -0.4% | N/A | |
 Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | 83.09M | 16.3% | 11.6% | -3.4% | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 5.09M | -23.9% | -2.1% | N/A | |
 Ocugen, Inc. NASDAQ:OCGN | 19.18M | -3.9% | 43.8% | 17.0% | |
 Lineage Cell Therapeutics, Inc. AMEX:LCTX | 53.43M | -5.1% | -3.2% | -7.5% | |
 Omeros Corporation NASDAQ:OMER | 109.97M | -11.8% | -8.5% | 31.7% |
Alumis Inc. Common Stock Fair Value Envelope
Related Guides
Continue your ALMS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.